CAPR - Capricor Therapeutics Inc. (CAPR) Q1 2024 Earnings Call Transcript

2024-05-14 03:03:07 ET

Capricor Therapeutics, Inc. (CAPR)

Q1 2024 Earnings Call Transcript

May 13, 2024, 04:30 PM ET

Company Participants

AJ Bergmann - CFO

Linda Marban - CEO

Conference Call Participants

Kristen Kluska - Cantor Fitzgerald

Ted Tenthoff - Piper Sandler

Joe Pantginis - H.C. Wainwright

Aydin Huseynov - Ladenburg Thalmann & Co.

Presentation

Operator

Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics First Quarter 2024 Earnings Call. At this time, all lines are in a listen-only mode. Following the presentation, We will conduct a question-and-answer session. Instructions will be provided at that time for you to get up for a question. [Operator Instructions] I would now like to turn the conference over to AJ Bergmann. Please go ahead.

AJ Bergmann

Thank you, and good afternoon, everyone. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our product candidates, our future research and development plans, including our anticipated conduct and timing of preclinical and clinical studies, our enrollment of patients in our clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates, revenue and reimbursement estimates, manufacturing capabilities, potential milestone payments, our financial position and our possible uses of existing cash and investment resources. These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update such statements.

With that, I'll turn the call over to Linda Marban, CEO.

Linda Marban

Thanks, AJ. Good afternoon, and thank you for joining today's first quarter conference call. 2024 has started off with a tremendous amount of progress for Capricor, and I'm delighted to provide updates on our Duchenne Muscular Dystrophy Program as well as providing update on our exosome platform technology....

For further details see: